BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Doktorego eskola
Royal North Shore Hospital
St Leonards, AustraliaRoyal North Shore Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (4)
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477
-
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
Journal of Hematology and Oncology, Vol. 7, Núm. 1
-
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Biomarker Research, Vol. 2, Núm. 1
2012
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
Journal of Clinical Oncology, Vol. 30, Núm. 6, pp. 631-636